Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Glenmark Pharmaceuticals Limited — Q2 FY25
Glenmark's Q2 FY25 consolidated revenue grew 7.1% YoY to INR 3,434 crore, driven by strong India (13.9% YoY) and Europe (14.6% YoY) performance, partially offset by a 1.2% decline in North America and 4.1% decline in ROW.
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Glenmark's Q2 FY25 consolidated revenue grew 7.1% YoY to INR 3,434 crore, driven by strong India (13.9% YoY) and Europe (14.6% YoY) performance, partially offset by a 1.2% decline in North America and 4.1% decline in ROW. India outperformed the IPM with 12.7% growth, while Europe benefited from branded respiratory uptake. The US business remains under pressure but expects improvement from new launches in H2. Management guided for full-year EBITDA margin of ~19% and expects Monroe plant to resume commercial production by end of FY25. Key growth drivers include RYALTRIS (targeting $200M+ sales), respiratory pipeline, and IGI's ISB 2001 with promising Phase 1 data. Risk: US price erosion and delayed Monroe ramp-up could pressure margins.
ग्लेनमार्क की दूसरी तिमाही में कुल कमाई 7.1% बढ़कर 3,434 करोड़ रुपये हुई। भारत में 13.9% और यूरोप में 14.6% की मजबूत बिक्री बढ़ी, जबकि उत्तर अमेरिका में 1.2% और बाकी दुनिया में 4.1% गिरावट आई। भारत में कंपनी ने बाजार से बेहतर प्रदर्शन किया। यूरोप में सांस की दवाओं की बिक्री बढ़ी। अमेरिका में दबाव है, लेकिन नए उत्पादों से सुधार की उम्मीद है। कंपनी का अनुमान है कि पूरे साल मुनाफा मार्जिन लगभग 19% रहेगा और मुनरो फैक्ट्री साल के अंत तक उत्पादन शुरू कर देगी। मुख्य वृद्धि RYALTRIS (200 मिलियन डॉलर से अधिक बिक्री लक्ष्य), सांस की दवाओं और IGI की नई दवा से होगी। जोखिम: अमेरिका में कीमतों में गिरावट और मुनरो फैक्ट्री में देरी से मुनाफा कम हो सकता है।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
US price erosion and competitive pressure
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
India Formulation Growth (IQVIA)
12.7%
+5.1pp vs IPM
Glenmark's India business grew 12.7% in Q2 FY25 vs IPM growth of 7.6%.
RYALTRIS Annual Sales Run Rate
$80M
N/A
RYALTRIS is tracking at ~$80M annual sales, with a target to reach $200M+ in 3-5 years.
ISB 2001 Overall Response Rate
75%
N/A
Phase 1 data for ISB 2001 showed 75% ORR in evaluable patients with favorable safety.
Monroe Plant Annual OpEx
$25-26M
N/A
Monroe plant incurs $25-26M annual operating expenses; resumption expected by end of FY25.
What Changed vs Last Quarter
NEW
Monroe plant resumption by end of FY25
Management expects to reinitiate commercial production at Monroe before end of FY25, following FDA meeting.
NEW
First respiratory launch in 6-9 months
Glenmark expects to launch its first respiratory product in the US within 6-9 months, pending approval.
UPDATED
Full-year EBITDA margin of ~19%
Management expects FY25 EBITDA margin to be close to 19%, with gradual improvement of 1-1.5% per year thereafter.
UPDATED
IGI partnership for ISB 2001 by FY26
Management aims to initiate partnering discussions post-ASH 2024 and expects a deal by FY26.
DROPPED
RYALTRIS sales target of $80 million in FY25
Management reiterated the target of $80 million in RYALTRIS sales for the full year, with new market launches expected in FY26.
DROPPED
US recovery expected in H2 FY25
Management expects US business to recover in the second half of FY25, driven by respiratory product approvals and Monroe facility restart.
NEW RISK
US price erosion and competitive pressure
US generic market faces low single-digit price erosion; margins remain under pressure from competition.
NEW RISK
Monroe plant delay
Monroe plant has been non-operational; any further delay in FDA clearance could prolong the $25-26M annual cash burn.
NEW RISK
Supply constraints for Lirafit
Lirafit (GLP-1 biosimilar) faced supply issues; resolution expected from December but could impact scaling.
NEW RISK
ROW growth slowdown
ROW revenue declined 4.1% YoY due to high base and geopolitical challenges; full-year growth guided at high single digit.
RISK GONE
USFDA delays at Monroe and Goa facilities
Monroe facility has an FDA meeting in September 2024, but no restart timeline; Goa remediation completed but inspection pending. Delays could impact US launches.
RISK GONE
GLP-1 market shift post-2026
Semaglutide patent expiry in 2026 may shift patients from liraglutide to newer GLP-1s, potentially limiting liraglutide's revenue potential.
RISK GONE
Working capital increase
CFO guided working capital days to increase to ~75 days from current 62 days, driven by business growth and receivables, which could pressure cash flows.
🤫 Topics management stopped discussing
Mentioned in Q2 FY24, Q4 FY24
EBITDA margin expected to be near 19% for full year FY25, supported by mix improvement and cost control.
Mentioned in Q1 FY24, Q2 FY24
Europe business expected to grow at a minimum of 15-20% going forward, driven by respiratory portfolio and Ryaltris.
Mentioned in Q1 FY24, Q2 FY24
India business growth was impacted by slowdown in respiratory and dermatology; while October showed recovery, sustainability is uncertain.
Mentioned in Q2 FY24, Q4 FY24
Remediation completed but FDA reinspection pending; delay could impact injectable commercialization timeline.
Mentioned in Q1 FY25, Q3 FY24
Management reiterated the target of $80 million in RYALTRIS sales for the full year, with new market launches expected in FY26.
Fast read
Guidance and risk preview
Management expects FY25 EBITDA margin to be close to 19%, with gradual improvement of 1-1.5% per year thereafter.
US generic market faces low single-digit price erosion; margins remain under pressure from competition.
View Risks →